Endocrinology and Metabolism

Original Articles

Thyroid
Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Jinsun Lim, Han Sai Lee, Jin-Hyung Heo, Young Shin Song; Endocrinol Metab. 2024;39(2):324-333. Published online April 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1885

377 View
18 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The predictive factors for lateral neck lymph node metastasis (LLNM) in papillary thyroid microcarcinoma (PTMC) remain undetermined. This study investigated the clinicopathological characteristics, transcriptomes, and tumor microenvironment in PTMC according to the LLNM status. We aimed to identify the biomarkers associated with LLNM development.
Methods
We retrospectively reviewed the medical records of patients with PTMC from two independent institutions between 2018 and 2022 (n=597 and n=467). We compared clinicopathological features between patients without lymph node metastasis (N0) and those with LLNM (N1b). Additionally, laser capture microdissection and RNA sequencing were performed on primary tumors from both groups, including metastatic lymph nodes from the N1b group (n=30; 20 primary tumors and 10 paired LLNMs). We corroborated the findings using RNA sequencing data from 16 BRAF-like PTMCs from The Cancer Genome Atlas. Transcriptomic analyses were validated by immunohistochemical staining.
Results
Clinicopathological characteristics, such as male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis showed associations with LLNM in PTMCs. Transcriptomic profiles between the N0 and N1b PTMC groups were similar. However, tumor microenvironment deconvolution from RNA sequencing and immunohistochemistry revealed an increased abundance of tumor-associated macrophages, particularly M2 macrophages, in the N1b group.
Conclusion
Patients with PTMC who have a male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis exhibited an elevated risk for LLNM. Furthermore, infiltration of M2 macrophages in the tumor microenvironment potentially supports tumor progression and LLNM in PTMCs.

Thyroid
Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study: Min-Su Kim, Jang Won Lee, Min Kyung Hyun, Young Shin Song; Endocrinol Metab. 2024;39(2):288-299. Published online March 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1815

680 View
37 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Current research has not investigated the effect of thyroid-stimulating hormone suppression therapy with levothyroxine on the risk for developing subsequent primary cancers (SPCs). This study aimed to investigate the association between levothyroxine dosage and the risk for SPCs in thyroid cancer patients.
Methods
We conducted a nationwide population-based retrospective cohort study form Korean National Health Insurance database. This cohort included 342,920 thyroid cancer patients between 2004 and 2018. Patients were divided into the non-levothyroxine and the levothyroxine groups, the latter consisting of four dosage subgroups according to quartiles. Cox proportional hazard models were performed to evaluate the risk for SPCs by adjusting for variables including cumulative doses of radioactive iodine (RAI) therapy.
Results
A total of 17,410 SPC cases were observed over a median 7.3 years of follow-up. The high-dose levothyroxine subgroups (Q3 and Q4) had a higher risk for SPC (adjusted hazard ratio [HR], 1.14 and 1.27; 95% confidence interval [CI], 1.05–1.24 and 1.17– 1.37; respectively) compared to the non-levothyroxine group. In particular, the adjusted HR of stomach (1.31), colorectal (1.60), liver and biliary tract (1.95), and pancreatic (2.48) cancers were increased in the Q4 subgroup. We consistently observed a positive association between high levothyroxine dosage per body weight and risk of SPCs, even after adjusting for various confounding variables. Moreover, similar results were identified in the stratified analyses according to thyroidectomy type and RAI therapy, as well as in a subgroup analysis of patients with good adherence.
Conclusion
High-dose levothyroxine use was associated with increased risk of SPCs among thyroid cancer patients regardless of RAI therapy.

Review Article

Thyroid
Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines: Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park; Endocrinol Metab. 2024;39(1):47-60. Published online February 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.1937

1,897 View
173 Download

Abstract PDF PubReader ePub: The indolent nature and favorable outcomes associated with papillary thyroid microcarcinoma have prompted numerous prospective studies on active surveillance (AS) and its adoption as an alternative to immediate surgery in managing low-risk thyroid cancer. This article reviews the current status of AS, as outlined in various international practice guidelines. AS is typically recommended for tumors that measure 1 cm or less in diameter and do not exhibit aggressive subtypes on cytology, extrathyroidal extension, lymph node metastasis, or distant metastasis. To determine the most appropriate candidates for AS, factors such as tumor size, location, multiplicity, and ultrasound findings are considered, along with patient characteristics like medical condition, age, and family history. Moreover, shared decision-making, which includes patient-reported outcomes such as quality of life and cost-effectiveness, is essential. During AS, patients undergo regular ultrasound examinations to monitor for signs of disease progression, including tumor growth, extrathyroidal extension, or lymph node metastasis. In conclusion, while AS is a feasible and reliable approach for managing lowrisk thyroid cancer, it requires careful patient selection, effective communication for shared decision-making, standardized follow-up protocols, and a clear definition of disease progression.

Original Articles

Thyroid
Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma: Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song; Endocrinol Metab. 2023;38(4):445-454. Published online July 18, 2023; DOI: https://doi.org/10.3803/EnM.2023.1702

1,630 View
102 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Papillary thyroid carcinoma (PTC) can be classified into two distinct molecular subtypes, BRAF-like (BL) and RASlike (RL). However, the molecular characteristics of each subtype according to clinicopathological factors have not yet been determined. We aimed to investigate the gene signatures and tumor microenvironment according to clinicopathological factors, and to identify the mechanism of progression in BL-PTCs and RL-PTCs.
Methods
We analyzed RNA sequencing data and corresponding clinicopathological information of 503 patients with PTC from The Cancer Genome Atlas database. We performed differentially expressed gene (DEG), Gene Ontology, and molecular pathway enrichment analyses according to clinicopathological factors in each molecular subtype. EcoTyper and CIBERSORTx were used to deconvolve the tumor cell types and their surrounding microenvironment.
Results
Even for the same clinicopathological factors, overlapping DEGs between the two molecular subtypes were uncommon, indicating that BL-PTCs and RL-PTCs have different progression mechanisms. Genes related to the extracellular matrix were commonly upregulated in BL-PTCs with aggressive clinicopathological factors, such as old age (≥55 years), presence of extrathyroidal extension, lymph node metastasis, advanced tumor-node-metastasis (TNM) stage, and high metastasis-age-completeness of resection- invasion-size (MACIS) scores (≥6). Furthermore, in the deconvolution analysis of tumor microenvironment, cancer-associated fibroblasts were significantly enriched. In contrast, in RL-PTCs, downregulation of immune response and immunoglobulin-related genes was significantly associated with aggressive characteristics, even after adjusting for thyroiditis status.
Conclusion
The molecular phenotypes of cancer progression differed between BL-PTC and RL-PTC. In particular, extracellular matrix and cancer-associated fibroblasts, which constitute the tumor microenvironment, would play an important role in the progression of BL-PTC that accounts for the majority of advanced PTCs.

Thyroid Thyroid Cancer Screening
Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis: Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park; Endocrinol Metab. 2023;38(1):93-103. Published online February 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.1667

2,181 View
117 Download
3 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Thyroid cancer screening has contributed to the skyrocketing prevalence of thyroid cancer. However, the true benefit of thyroid cancer screening is not fully understood. This study aimed to evaluate the impact of screening on the clinical outcomes of thyroid cancer by comparing incidental thyroid cancer (ITC) with non-incidental thyroid cancer (NITC) through a meta-analysis.
Methods
PubMed and Embase were searched from inception to September 2022. We estimated and compared the prevalence of high-risk features (aggressive histology of thyroid cancer, extrathyroidal extension, metastasis to regional lymph nodes or distant organs, and advanced tumor-node-metastasis [TNM] stage), thyroid cancer-specific death, and recurrence in the ITC and NITC groups. We also calculated pooled risks and 95% confidence intervals (CIs) of the outcomes derived from these two groups.
Results
From 1,078 studies screened, 14 were included. In comparison to NITC, the ITC group had a lower incidence of aggressive histology (odds ratio [OR], 0.46; 95% CI, 0.31 to 0.7), smaller tumors (mean difference, −7.9 mm; 95% CI, −10.2 to −5.6), lymph node metastasis (OR, 0.64; 95% CI, 0.48 to 0.86), and distant metastasis (OR, 0.42; 95% CI, 0.23 to 0.77). The risks of recurrence and thyroid cancer-specific mortality were also lower in the ITC group (OR, 0.42; 95% CI, 0.25 to 0.71 and OR, 0.46; 95% CI, 0.28 to 0.74) than in the NITC group.
Conclusion
Our findings provide important evidence of a survival benefit from the early detection of thyroid cancer compared to symptomatic thyroid cancer.

Citations

Citations to this article as recorded by

To Screen or Not to Screen?
Do Joon Park
Endocrinology and Metabolism.2023; 38(1): 69. CrossRef
The 2017 United States Preventive Services Task Force Recommendation for Thyroid Cancer Screening Is No Longer the Gold Standard
Ka Hee Yi
Endocrinology and Metabolism.2023; 38(1): 72. CrossRef
Thyroid Cancer Screening: How to Maximize Its Benefits and Minimize Its Harms
Jung Hwan Baek
Endocrinology and Metabolism.2023; 38(1): 75. CrossRef
Delayed Surgery for and Outcomes of Papillary Thyroid Cancer: Is the Pendulum Still Swinging?
Giorgio Grani
Clinical Thyroidology.2023; 35(5): 192. CrossRef

Endocrine Research
DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption: Min Joo Kim, Hwan Hee Kim, Young Shin Song, Ok-Hee Kim, Kyungho Choi, Sujin Kim, Byung-Chul Oh, Young Joo Park; Endocrinol Metab. 2021;36(2):447-454. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.920

5,048 View
145 Download
12 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Di-2-ethylhexyl phthalate (DEHP) is known to disrupt thyroid hormonal status. However, the underlying molecular mechanism of this disruption is unclear. Therefore, we investigated the direct effects of DEHP on the thyroid gland.
Methods
DEHP (vehicle, 50 mg/kg, and 500 mg/kg) was administered to Sprague-Dawley rats for 2 weeks. The expression of the thyroid hormone synthesis pathway in rat thyroid tissues was analyzed through RNA sequencing analysis, quantitative reverse transcription-polymerase chain reaction (RT-PCR), and immunohistochemical (IHC) staining. DEHP was treated to FRTL-5 rat thyroid cells, and an RT-PCR analysis was performed. A reporter gene assay containing the promoter of thyroid stimulating hormone receptor (TSHR) in Nthy-ori 3-1 human thyroid cells was constructed, and luciferase activity was determined.
Results
After DEHP treatment, the free thyroxine (T4) and total T4 levels in rats significantly decreased. RNA sequencing analysis of rat thyroid tissues showed little difference between vehicle and DEHP groups. In the RT-PCR analysis, Tshr expression was significantly lower in both DEHP groups (50 and 500 mg/kg) compared to that in the vehicle group, and IHC staining showed that TSHR expression in the 50 mg/kg DEHP group significantly decreased. DEHP treatment to FRTL-5 cells significantly down-regulated Tshr expression. DEHP treatment also reduced luciferase activity in a reporter gene assay for TSHR.
Conclusion
Although overall genetic changes in the thyroid hormone synthesis pathway are not clear, DEHP exposure could significantly down-regulate Tshr expression in thyroid glands. Down-regulation of Tshr gene appears to be one of potential mechanisms of thyroid disruption by DEHP exposure.

Citations

Citations to this article as recorded by

ARTS is essential for di-2-ethylhexyl phthalate (DEHP)-induced apoptosis of mouse Leydig cells
Yue Li, Linlin Xu, Chaoju Hao, Si Yang, Jinglei Wang, Jiaxiang Chen
Ecotoxicology and Environmental Safety.2024; 270: 115882. CrossRef
Thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review
Jie He, Jie Xu, Mucong Zheng, Kai Pan, Lilin Yang, Lina Ma, Chuyang Wang, Jie Yu
Chemico-Biological Interactions.2024; 391: 110909. CrossRef
Intrauterine exposure to di(2-ethylhexyl) phthalate (DEHP) disrupts the function of the hypothalamus-pituitary-thyroid axis of the F1 rats during adult life
Érica Kássia Sousa-Vidal, Guilherme Henrique, Renata Elen Costa da Silva, Caroline Serrano-Nascimento
Frontiers in Endocrinology.2023;[Epub] CrossRef
Drinking water disinfection byproduct iodoacetic acid affects thyroid hormone synthesis in Nthy-ori 3–1 cells
Jingyi Xiao, Yujie Sha, Yuwen Huang, Kunling Long, Huan Wu, Yan Mo, Qiyuan Yang, Shengkun Dong, Qiang Zeng, Xiao Wei
Ecotoxicology and Environmental Safety.2023; 257: 114926. CrossRef
Assessment of five typical environmental endocrine disruptors and thyroid cancer risk: a meta-analysis
Yuyao Yang, Xiaoyue Bai, Juan Lu, Ronghao Zou, Rui Ding, Xiaohui Hua
Frontiers in Endocrinology.2023;[Epub] CrossRef
Investigation of the effects of phthalates on in vitro thyroid models with RNA-Seq and ATAC-Seq
Marta Nazzari, Mírian Romitti, Duncan Hauser, Daniel J. Carvalho, Stefan Giselbrecht, Lorenzo Moroni, Sabine Costagliola, Florian Caiment
Frontiers in Endocrinology.2023;[Epub] CrossRef
Di(2-ethylhexyl) phthalate (DEHP) and thyroid: biological mechanisms of interference and possible clinical implications
Xueting Zhang, Wen Qi, Qi Xu, Xu Li, Liting Zhou, Lin Ye
Environmental Science and Pollution Research.2022; 29(2): 1634. CrossRef
The possible thyroid disruptive effect of di-(2-ethyl hexyl) phthalate and the potential protective role of selenium and curcumin nanoparticles: a toxicological and histological study
Naima Abd El-Halim Sherif, Asmaa El-Banna, Rehab Ahmed Abdel-Moneim, Zahraa Khalifa Sobh, Manal Ibrahim Fathy Balah
Toxicology Research.2022; 11(1): 108. CrossRef
Environmental disruption of reproductive rhythms
Marie-Azélie Moralia, Clarisse Quignon, Marine Simonneaux, Valérie Simonneaux
Frontiers in Neuroendocrinology.2022; 66: 100990. CrossRef
Endocrine-disruptor endpoints in the ovary and thyroid of adult female rats exposed to realistic doses of di-(2-ethylhexyl) phthalate
Amel Jebara, Asma Beltifa, Guissepa Di Bella, Lotfi Mabrouk, Hedi Ben Mansour
Journal of Water and Health.2022; 20(8): 1256. CrossRef
The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae
Gang Wei, Cao-xu Zhang, Yu Jing, Xia Chen, Huai-dong Song, Liu Yang
Chemosphere.2022; 308: 136354. CrossRef
Role of estrogen receptors in thyroid toxicity induced by mono (2-ethylhexyl) phthalate via endoplasmic reticulum stress: An in vitro mechanistic investigation
Qi Xu, Liting Zhou, Hyonju Ri, Xu Li, Xueting Zhang, Wen Qi, Lin Ye
Environmental Toxicology and Pharmacology.2022; 96: 104007. CrossRef

Review Articles

Thyroid
Mechanisms of TERT Reactivation and Its Interaction with BRAF^V600E: Young Shin Song, Young Joo Park; Endocrinol Metab. 2020;35(3):515-525. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.304

7,915 View
198 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

The telomerase reverse transcriptase (TERT) gene, which is repressed in most differentiated human cells, can be reactivated by somatic TERT alterations and epigenetic modulations. Moreover, the recruitment, accessibility, and binding of transcription factors also affect the regulation of TERT expression. Reactivated TERT contributes to the development and progression of cancer through telomere lengthening-dependent and independent ways. In particular, because of recent advances in high-throughput sequencing technologies, studies on genomic alterations in various cancers that cause increased TERT transcriptional activity have been actively conducted. TERT reactivation has been reported to be associated with poor prognosis in several cancers, and TERT promoter mutations are among the most potent prognostic markers in thyroid cancer. In particular, when a TERT promoter mutation coexists with the BRAF^V600E mutation, these mutations exert synergistic effects on a poor prognosis. Efforts have been made to uncover the mechanisms of these synergistic interactions. In this review, we discuss the role of TERT reactivation in tumorigenesis, the mechanisms of TERT reactivation across all human cancers and in thyroid cancer, and the mechanisms of interactions between BRAF^V600E and TERT promoter mutations.

Citations

Citations to this article as recorded by

Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing
Lili Deng, Jingjing Zeng, Jin Feng Qiu, Li Hua Yang, Jie Ma
Medicine.2023; 102(32): e34523. CrossRef
Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas
Alexander T. Kikuchi, Sarah Umetsu, Nancy Joseph, Sanjay Kakar
American Journal of Surgical Pathology.2023; 47(11): 1207. CrossRef
Telomerase and hallmarks of cancer: An intricate interplay governing cancer cell evolution
Naveen kumar, Gautam Sethi
Cancer Letters.2023; 578: 216459. CrossRef
Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile
Ivana Kholová, Elina Haaga, Jaroslav Ludvik, David Kalfert, Marie Ludvikova
Diagnostics.2022; 12(2): 250. CrossRef
Does Locally Advanced Thyroid Cancer Have Different Features? Results from a Single Academic Center
Marco Dell’Aquila, Pietro Tralongo, Giuseppe De Ruggieri, Mariangela Curatolo, Luca Revelli, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda, Luigi Maria Larocca, Marco Raffaelli, Liron Pantanowitz, Esther Diana Rossi
Journal of Personalized Medicine.2022; 12(2): 221. CrossRef
Adult Wilms Tumor
Pedram Argani, Satish K. Tickoo, Andres Matoso, Christine A. Pratilas, Rohit Mehra, Maria Tretiakova, Mathilde Sibony, Alan K. Meeker, Ming-Tseh Lin, Victor E. Reuter, Jonathan I. Epstein, Jeffrey Gagan, Doreen N. Palsgrove
American Journal of Surgical Pathology.2022; 46(7): 988. CrossRef
Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
Yun-Suk Choi, Seong-Woon Choi, Jin-Wook Yi
Journal of Clinical Medicine.2021; 10(10): 2179. CrossRef
How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid‐based cytology: Role of TERT promoter and BRAF V600E mutation analysis
Marco Dell’Aquila, Vincenzo Fiorentino, Maurizio Martini, Sara Capodimonti, Tonia Cenci, Celestino Pio Lombardi, Marco Raffaelli, Alfredo Pontecorvi, Guido Fadda, Liron Pantanowitz, Luigi Maria Larocca, Esther Diana Rossi
Cancer Cytopathology.2021; 129(10): 819. CrossRef
Human telomerase reverse transcriptase and telomeres in cancer
Anurag Mehta, Shrinidhi Nathany
Journal of Current Oncology.2021; 4(1): 1. CrossRef
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
Eyun Song, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong, Won Gu Kim
Cancers.2021; 13(22): 5846. CrossRef

Thyroid
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers: Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo; Endocrinol Metab. 2020;35(1):44-54. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.44

7,234 View
242 Download
16 Web of Science
18 Crossref

Abstract PDF PubReader ePub

Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.

Citations

Citations to this article as recorded by

The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
Peter Y.F. Zeng, Stephenie D. Prokopec, Stephen Y. Lai, Nicole Pinto, Michelle A. Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D. Williams, Christopher J. Howlett, Paul Plantinga, Matthew J. Cecchini, Alfred K. Lam, Iram Siddiqui, Jianxin Wang, Ren X.
Cell Reports.2024; 43(3): 113826. CrossRef
Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation
Kun Zhang, Xinyi Wang, Tao Wei, Zhihui Li, Jingqiang Zhu, Ya-Wen Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres
C. Lorimer, L. Cheng, R. Chandler, K. Garcez, V. Gill, K. Graham, W. Grant, S. Sardo Infirri, J. Wadsley, L. Wall, N. Webber, K.H. Wong, K. Newbold
Clinical Oncology.2023; 35(1): e60. CrossRef
MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions
E. Macerola, A. M. Poma, P. Vignali, A. Proietti, L. Torregrossa, C. Ugolini, A. Basolo, A. Matrone, R. Elisei, F. Santini, F. Basolo
Journal of Endocrinological Investigation.2023; 46(8): 1651. CrossRef
RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex
Debin Xu, Jichun Yu, Yuting Yang, Yunyan Du, Hongcheng Lu, Shouhua Zhang, Qian Feng, Yi Yu, Liang Hao, Jun Shao, Leifeng Chen
Cell & Bioscience.2023;[Epub] CrossRef
Multi-Omics and Management of Follicular Carcinoma of the Thyroid
Thifhelimbilu Emmanuel Luvhengo, Ifongo Bombil, Arian Mokhtari, Maeyane Stephens Moeng, Demetra Demetriou, Claire Sanders, Zodwa Dlamini
Biomedicines.2023; 11(4): 1217. CrossRef
Genomic landscape of anaplastic thyroid cancer and implications on therapy
Leslie Cheng, Kate Newbold
Current Opinion in Endocrine and Metabolic Research.2023; 30: 100458. CrossRef
Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
Frontiers in Immunology.2023;[Epub] CrossRef
Characterization of the genomic alterations in poorly differentiated thyroid cancer
Yeeun Lee, SeongRyeol Moon, Jae Yeon Seok, Joon-Hyop Lee, Seungyoon Nam, Yoo Seung Chung
Scientific Reports.2023;[Epub] CrossRef
Genetica del carcinoma anaplastico della tiroide
Teresa Ramone, Chiara Mulè, Cristina Romei, Raffaele Ciampi, Eleonora Molinaro, Rossella Elisei
L'Endocrinologo.2022; 23(2): 208. CrossRef
Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato, Fabio Biagio La Torre, Jerry Polesel, Elisabetta Fratta, Vittorio Giacomarra, Giovanni Franchin, Agostino Steffan, Michele Spina, Salvatore Alfieri
Critical Reviews in Oncology/Hematology.2022; 175: 103707. CrossRef
Recent Improvements in the Treatment of High-Risk Thyroid Cancer
Eun Kyung Lee
Korean Society for Head and Neck Oncology.2022; 38(1): 1. CrossRef
Inhibition of Glycogen Metabolism Induces Reactive Oxygen Species-Dependent Cytotoxicity in Anaplastic Thyroid Cancer in Female Mice
Cole D Davidson, Jennifer A Tomczak, Eyal Amiel, Frances E Carr
Endocrinology.2022;[Epub] CrossRef
Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis
Hao Zhao, Chun-Hao Liu, Yue Cao, Li-Yang Zhang, Ya Zhao, Yue-Wu Liu, Hong-Feng Liu, Yan-Song Lin, Xiao-Yi Li
Frontiers in Oncology.2022;[Epub] CrossRef
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Saw
Thyroid.2021; 31(3): 337. CrossRef
Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
Journal of Personalized Medicine.2021; 11(5): 333. CrossRef
The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment
Siarhei A. Dabravolski, Nikita G. Nikiforov, Alexander D. Zhuravlev, Nikolay A. Orekhov, Liudmila M. Mikhaleva, Alexander N. Orekhov
International Journal of Molecular Sciences.2021; 23(1): 460. CrossRef
Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
Young Shin Song, Young Joo Park
Endocrinology and Metabolism.2020; 35(3): 515. CrossRef

Namgok Lecture 2018

Thyroid
Genomic Characterization of Differentiated Thyroid Carcinoma: Young Shin Song, Young Joo Park; Endocrinol Metab. 2019;34(1):1-10. Published online March 21, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.1

7,079 View
210 Download
36 Web of Science
36 Crossref

Abstract PDF PubReader ePub

Since the release of The Cancer Genome Atlas study of papillary thyroid carcinoma (PTC) in 2014, additional genomic studies of differentiated thyroid carcinoma (DTC) using massively-parallel sequencing (MPS) have been published. Recent advances in MPS technology have started to provide important insights into the molecular pathogenesis of DTC. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are BRAF, RAS, and fusion genes. Some novel driver candidates also have been identified. The frequency of these genomic alterations varies across the subtypes of DTC (classical PTC, follicular variant of PTC, and follicular thyroid carcinoma). Telomerase reverse transcriptase (TERT) promoter mutations are the alteration that makes the most important contribution to the progression of DTC. In the transcriptomic landscape, DTC can be classified according to its gene expression profile, and each subtype has a distinct mutational profile, intracellular signaling output, and clinicopathological characteristics. Herein, we review the results of genomic studies using MPS technology, and describe the types and frequencies of genomic alterations according to histological classifications of DTC and the characteristics and significance of the gene expression signatures of DTC.

Citations

Citations to this article as recorded by

Radiation-Related Thyroid Cancer
Vladimir Saenko, Norisato Mitsutake
Endocrine Reviews.2024; 45(1): 1. CrossRef
TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases
Marie-Lisa Eich, Wiebke Jeske, Uschi Zenz, Costanza Chiapponi, Christina Alidousty, Sabine Merkelbach-Bruse, Reinhard Büttner, Anne M. Schultheis
Thyroid Research.2024;[Epub] CrossRef
Molecular testing in fine‐needle aspiration of thyroid nodules
Valarie McMurtry, Sule Canberk, Georgios Deftereos
Diagnostic Cytopathology.2023; 51(1): 36. CrossRef
A Triumvirate:
Jaylou M. Velez Torres, Youley Tjendra, Darcy A. Kerr
Surgical Pathology Clinics.2023; 16(1): 1. CrossRef
Current Status and Prospects of Chemotherapy in Treatment of Distant Metastatic or Recurrent Thyroid Cancer
T. Yamazaki
Nihon Kikan Shokudoka Gakkai Kaiho.2023; 74(2): 141. CrossRef
FDG uptake reflects an immune‐enriched subtype of thyroid cancer: Clinical implications of imaging‐based molecular characterization
Hoon Young Suh, Hongyoon Choi, Sun Wook Cho, Jin Chul Paeng, Gi Jeong Cheon, Young Joo Park, Keon Wook Kang
Cancer Medicine.2023; 12(16): 17068. CrossRef
Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review)
Shici Yang, Gaohong Zhu, Rui He, Dong Fang, Jiaojiao Feng
Oncology Letters.2023;[Epub] CrossRef
Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song
Endocrinology and Metabolism.2023; 38(4): 445. CrossRef
Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review)
Abdul-Mohsen Alhejaily, Omar Alhuzim, Yazeed Alwelaie
Molecular and Clinical Oncology.2023;[Epub] CrossRef
Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea
Jandee Lee, Seonhyang Jeong, Hwa Young Lee, Sunmi Park, Meesson Jeong, Young Suk Jo
Endocrinology and Metabolism.2023; 38(6): 720. CrossRef
Problems of follicular thyroid carcinoma diagnostics
S. E. Titov, S. A. Lukyanov, S. V. Sergiyko, Yu. A. Veryaskina, T. E. Ilyina, E. S. Kozorezov, S. L. Vorobyov
Head and Neck Tumors (HNT).2023; 13(3): 10. CrossRef
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Cancer Treatment Reviews.2022; 105: 102372. CrossRef
Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology
Myat Han Soe, Janet M Chiang, Robert R Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3206. CrossRef
Recent Improvements in the Treatment of High-Risk Thyroid Cancer
Eun Kyung Lee
Korean Society for Head and Neck Oncology.2022; 38(1): 1. CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef
Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
Denis Horgan, Dagmar Führer-Sakel, Paula Soares, Clara V. Alvarez, Laura Fugazzola, Romana T. Netea-Maier, Barbara Jarzab, Marta Kozaric, Beate Bartes, James Schuster-Bruce, Luigino Dal Maso, Martin Schlumberger, Furio Pacini
Healthcare.2022; 10(9): 1621. CrossRef
The role of EZH1 and EZH2 in development and cancer
Soo Hyun Lee, Yingying Li, Hanbyeol Kim, Seounghyun Eum, Kyumin Park, Chul-Hwan Lee
BMB Reports.2022; 55(12): 595. CrossRef
The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer
Justyna Mika, Wojciech Łabaj, Mykola Chekan, Agata Abramowicz, Monika Pietrowska, Andrzej Polański, Piotr Widłak
Journal of Applied Genetics.2021; 62(1): 115. CrossRef
Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer
Ying Wang, Zhigang Hu, Weiyuan Ma, Yong Niu, Jingwei Su, Lingxiang Zhang, Pengxin Zhao
Investigational New Drugs.2021; 39(3): 764. CrossRef
Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology
Tim Beck, Ning Zhang, Akeesha Shah, Sarah Khoncarly, Christopher McHenry, Judy Jin
Journal of Surgical Research.2021; 260: 245. CrossRef
Associations between artificial light at night and risk for thyroid cancer: A large US cohort study
Dong Zhang, Rena R. Jones, Peter James, Cari M. Kitahara, Qian Xiao
Cancer.2021; 127(9): 1448. CrossRef
Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.)
Chaiho Jeong, Jeonghoon Ha, Moo Il Kang
Endocrinology and Metabolism.2021; 36(1): 205. CrossRef
Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
Journal of Personalized Medicine.2021; 11(5): 333. CrossRef
Silencing circRNA protein kinase C iota (circ-PRKCI) suppresses cell progression and glycolysis of human papillary thyroid cancer through circ-PRKCI/miR-335/E2F3 ceRNA axis
Yan Liu, Gen Chen, Bo Wang, Hanjin Wu, Yi Zhang, Hui Ye
Endocrine Journal.2021; 68(6): 713. CrossRef
Multiparametric Photoacoustic Analysis of Human Thyroid Cancers In Vivo
Jeesu Kim, Byullee Park, Jeonghoon Ha, Idan Steinberg, Sarah M. Hooper, Chaiho Jeong, Eun-Yeong Park, Wonseok Choi, Tie Liang, Ja Seong Bae, Ravi Managuli, Yongmin Kim, Sanjiv S. Gambhir, Dong-Jun Lim, Chulhong Kim
Cancer Research.2021; 81(18): 4849. CrossRef
Thyroid Cancer Risk Factors in Children with Thyroid Nodules: A One-Center Study
Iwona Ben-Skowronek, Joanna Sieniawska, Emilia Pach, Wiktoria Wrobel, Anna Skowronek, Zaklina Tomczyk, Anna Mlodawska, Magdalena Makuch, Magdalena Malka, Czeslaw Cielecki, Pawel Nachulewicz
Journal of Clinical Medicine.2021; 10(19): 4455. CrossRef
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
Rita Niciporuka, Jurijs Nazarovs, Arturs Ozolins, Zenons Narbuts, Edvins Miklasevics, Janis Gardovskis
Medicina.2021; 57(10): 1131. CrossRef
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers
Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo
Endocrinology and Metabolism.2020; 35(1): 44. CrossRef
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Cancers.2020; 12(5): 1345. CrossRef
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances
Ying-Hsia Chu, Peter M. Sadow
Seminars in Diagnostic Pathology.2020; 37(5): 213. CrossRef
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
María San Román Gil, Javier Pozas, Javier Molina-Cerrillo, Joaquín Gómez, Héctor Pian, Miguel Pozas, Alfredo Carrato, Enrique Grande, Teresa Alonso-Gordoa
International Journal of Molecular Sciences.2020; 21(14): 4951. CrossRef
DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms
Philippe Vielh, Zsofia Balogh, Voichita Suciu, Catherine Richon, Bastien Job, Guillaume Meurice, Alexander Valent, Ludovic Lacroix, Virginie Marty, Nelly Motte, Philippe Dessen, Bernard Caillou, Abir Ghuzlan, Jean-Michel Bidart, Vladimir Lazar, Paul Hofma
Cancers.2020; 12(9): 2529. CrossRef
Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
Young Shin Song, Young Joo Park
Endocrinology and Metabolism.2020; 35(3): 515. CrossRef
Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China
Yuntao Song, Guohui Xu, Tonghui Ma, Yanli Zhu, Hao Yu, Wenbin Yu, Wei Wei, Tianxiao Wang, Bin Zhang
Cancer Medicine.2020; 9(22): 8397. CrossRef
Thyroid Cancer and Circadian Clock Disruption
Roberta Malaguarnera, Caterina Ledda, Agnese Filippello, Francesco Frasca, Vincenzo Cristian Francavilla, Tiziana Ramaci, Maria Chiara Parisi, Venerando Rapisarda, Salvatore Piro
Cancers.2020; 12(11): 3109. CrossRef
Molecular testing approaches in thyroid cancer diagnosis
Abdul-Mohsen AlHejaily, Naji AlJohani
Journal of Biochemical and Clinical Genetics.2020; : 77. CrossRef

Original Article

Clinical Study
Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort: Young Ah Lee, Sun Wook Cho, Ho Kyung Sung, Kyungsik Kim, Young Shin Song, Sin Je Moon, Jung Won Oh, Dal Lae Ju, Sooyeon Choi, Sang Hoon Song, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Sue K. Park, Jong Kwan Jun, June-Key Chung; Endocrinol Metab. 2018;33(3):395-402. Published online September 18, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.3.395

4,920 View
84 Download
1 Web of Science
2 Crossref

Abstract PDF PubReader ePub

Background

Iodine is an intrinsic element of thyroid hormone, which is essential for childhood growth and development. The Ideal Breast Milk (IBM) cohort study aims to evaluate the effects of maternal iodine status during pregnancy and lactation on maternal thyroid function, offspring growth and development, and offspring thyroid function.

Methods

The IBM cohort study recruited pregnant women from Seoul National University Hospital between June 2016 and August 2017, followed by enrollment of their offspring after delivery. For the maternal participants, iodine status is evaluated by urinary iodine concentration (UIC) and dietary records in the third trimester and at 3 to 4 weeks and 12 to 15 months postpartum. For the child participants, cord blood sampling and UIC measurements are performed at birth. At 3 to 4 weeks of age, UIC and breastmilk iodine concentrations are measured. At 12 to 15 months of age, growth and development are assessed and measurements of UIC, a thyroid function test, and ultrasonography are performed.

Results

A total of 198 pregnant women in their third trimester were recruited. Their mean age was 35.1±3.5 years, and 78 (39.4%) of them were pregnant with twins. Thirty-three (16.7%) of them had a previous history of thyroid disease.

Conclusion

Korea is an iodine-replete area. In particular, lactating women in Korea are commonly exposed to excess iodine due to the traditional practice of consuming brown seaweed soup postpartum. The study of the IBM cohort is expected to contribute to developing guidelines for optimal iodine nutrition in pregnant or lactating women.

Citations

Citations to this article as recorded by

High intakes of iodine among women during pregnancy and the postpartum period has no adverse effect on thyroid function
Dal Lae Ju, Sun Wook Cho, Chae Won Chung, Young Ah Lee, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Jong Kwan Jun, June-Key Chung, Sue K. Park, YoonJu Song
European Journal of Nutrition.2023; 62(1): 239. CrossRef
Associations between maternal thyroid function in pregnancy and child neurodevelopmental outcomes at 20 months in the Seychelles Child Development Study, Nutrition Cohort 2 (SCDS NC2)
Anna M. Monaghan, Maria S. Mulhern, Emeir M. Mc Sorley, J.J. Strain, Theresa Winter, Edwin van Wijngaarden, Gary J. Myers, Philip W. Davidson, Conrad Shamlaye, Jude Gedeon, Alison J. Yeates
Journal of Nutritional Science.2021;[Epub] CrossRef

Corrigendum

Miscellaneous
Corrigendum: Author's Name Correction. Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro): Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-Jin Jeong, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun-Jae Chung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park; Endocrinol Metab. 2018;33(3):427. Published online August 14, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.3.427

3,504 View
48 Download
2 Web of Science
2 Crossref

PDF PubReader ePub

Citations

Citations to this article as recorded by

Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population
Haytham Bayadsi, Martin Bergman, Malin Sund, Joakim Hennings
World Journal of Surgery.2020; 44(2): 461. CrossRef
Clinical and pathologic predictors of lymph node metastasis in papillary thyroid microcarcinomas
Ling Zhao, Xiaoya Sun, Yukun Luo, Fulin Wang, Zhaohui Lyu
Annals of Diagnostic Pathology.2020; 49: 151647. CrossRef

Original Articles

Thyroid
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro): Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park; Endocrinol Metab. 2018;33(2):278-286. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.278

5,436 View
88 Download
34 Web of Science
31 Crossref

Abstract PDF PubReader ePub

Background

The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups.

Methods

This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis.

Results

Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014).

Conclusion

The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.

Citations

Citations to this article as recorded by

Psychological adjustment to initial treatment for low‐risk thyroid cancer: Preliminary study
Gabriella T. Seo, Mark L. Urken, Lauren E. Wein, Michael P. Saturno, Danielle Kapustin, Monica H. Xing, Lauren E. Yue, Eric M. Dowling, Tracey A. Revenson, Katherine J. Roberts, Robert Michael Tuttle
Head & Neck.2023; 45(2): 439. CrossRef
Response to Letter to the Editor on Surgical Outcomes in Patients With Low-Risk Papillary Thyroid Microcarcinoma From MAeSTro Study: Immediate Operation Versus Delayed Operation Following Active Surveillance: A Multicenter Prospective Cohort Study
Hyeonuk Hwang, June Young Choi, Jae Hoon Moon, Eun Kyung Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jung
Annals of Surgery Open.2023; 4(3): e311. CrossRef
Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
Endocrinology and Metabolism.2023; 38(1): 93. CrossRef
To Screen or Not to Screen?
Do Joon Park
Endocrinology and Metabolism.2023; 38(1): 69. CrossRef
Surgical Outcomes in Patients With Low-risk Papillary Thyroid Microcarcinoma From MAeSTro Study
Hyeonuk Hwang, June Young Choi, Hyeong Won Yu, Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Yeo Koon Kim, Chang Yoon Lee, Sun Wook Cho, Eun-Jae Chung, Chang Hwan Ryu, Junsun Ryu, Ka Hee Yi, Do Joon Park, Kyu Eun Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jun
Annals of Surgery.2023; 278(5): e1087. CrossRef
US Predictors of Papillary Thyroid Microcarcinoma Progression at Active Surveillance
Ji Ye Lee, Ji-hoon Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Jae Hoon Moon, Hoon Sung Choi, Hwangbo Yul, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Do Joon Park, Young Joo Park
Radiology.2023;[Epub] CrossRef
MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer
Madelon J. H. Metman, Pascal K. C. Jonker, Luc H. J. Sondorp, Bettien M. van Hemel, Mark S. Sywak, Anthony J. Gill, Liesbeth Jansen, Paul J. van Diest, Tessa M. van Ginhoven, Clemens W. G. M. Löwik, Anh H. Nguyen, Dominic J. Robinson, Gooitzen M. van Dam,
European Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub] CrossRef
Active Surveillance of Thyroid Microcarcinomas: a Critical View
Claudio R. Cernea, Leandro Luongo Matos, Cecília Eugênio, Giovanna Mattos Ferreira, Yasmin Sa Cerqueira, Ana Kober N. Leite, Felipe A. B. Vanderlei, Dorival de Carlucci, Renato N. Gotoda, Flávio C. Hojaij, Vergilius J. F. Araújo-Filho
Current Oncology Reports.2022; 24(1): 69. CrossRef
Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
Roger Chou, Tracy Dana, Megan Haymart, Angela M. Leung, Ralph P. Tufano, Julie Ann Sosa, Matthew D. Ringel
Thyroid.2022; 32(4): 351. CrossRef
A Review of Active Surveillance of Papillary Thyroid Microcarcinoma
Cho Rok Lee
Journal of Endocrine Surgery.2022; 22(1): 1. CrossRef
Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study
Kyungsik Kim, June Young Choi, Su-jin Kim, Eun Kyung Lee, Young Ki Lee, Jun Sun Ryu, Kyu Eun Lee, Jae Hoon Moon, Young Joo Park, Sun Wook Cho, Sue K. Park
Thyroid.2022; 32(6): 648. CrossRef
A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro)
Yul Hwangbo, June Young Choi, Eun Kyung Lee, Chang Hwan Ryu, Sun Wook Cho, Eun Jae Chung, Jeong Hun Hah, Woo-Jin Jeong, Sue K. Park, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, You Jin Lee, Hyeong Won Yu,
Thyroid.2022;[Epub] CrossRef
Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea
Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee,
Thyroid.2022; 32(11): 1328. CrossRef
Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma
Iwao Sugitani, Yasuhiro Ito, Dai Takeuchi, Hirotaka Nakayama, Chie Masaki, Hisakazu Shindo, Masanori Teshima, Kazuhiko Horiguchi, Yusaku Yoshida, Toshiharu Kanai, Mitsuyoshi Hirokawa, Kiyomi Y. Hames, Isao Tabei, Akira Miyauchi
Thyroid.2021; 31(2): 183. CrossRef
Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724. CrossRef
Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey
Susan C Pitt, Nan Yang, Megan C Saucke, Nicholas Marka, Bret Hanlon, Kristin L Long, Alexandria D McDow, J P Brito, Benjamin R Roman
The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): 1728. CrossRef
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinology and Metabolism.2021; 36(2): 359. CrossRef
Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance
Ryuta Nagaoka, Aya Ebina, Kazuhisa Toda, Tomoo Jikuzono, Marie Saitou, Masaomi Sen, Hiroko Kazusaka, Mami Matsui, Keiko Yamada, Hiroki Mitani, Iwao Sugitani
World Journal of Surgery.2021; 45(9): 2769. CrossRef
Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2021; 36(4): 717. CrossRef
The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park
Endocrinology and Metabolism.2021; 36(4): 725. CrossRef
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Cancers.2020; 12(5): 1345. CrossRef
Experience with Active Surveillance of Thyroid Low-Risk Carcinoma in a Developing Country
Alvaro Sanabria
Thyroid.2020; 30(7): 985. CrossRef
Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance
Alexandra Koshkina, Rouhi Fazelzad, Iwao Sugitani, Akira Miyauchi, Lehana Thabane, David P. Goldstein, Sangeet Ghai, Anna M. Sawka
JAMA Otolaryngology–Head & Neck Surgery.2020; 146(6): 552. CrossRef
Active surveillance in low risk papillary thyroid carcinoma
Fabian Pitoia, Anabella Smulever
World Journal of Clinical Oncology.2020; 11(6): 320. CrossRef
Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Agnieszka Kotecka-Blicharz, Katarzyna Drosik-Rutowicz, Malgorzata Haras-Gil, Barbara Jarzab, Daria Handkiewicz-Junak
Frontiers in Endocrinology.2020;[Epub] CrossRef
The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
Juan C Galofré
Endocrinología, Diabetes y Nutrición.2019; 66(8): 469. CrossRef
Computed Tomography for Detecting Cervical Lymph Node Metastasis in Patients Who Have Papillary Thyroid Microcarcinoma with Tumor Characteristics Appropriate for Active Surveillance
Dong-Hwa Lee, Yeo Koon Kim, Hyeong Won Yu, June Young Choi, So Yeon Park, Jae Hoon Moon
Thyroid.2019; 29(11): 1653. CrossRef
The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
Juan C Galofré
Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(8): 469. CrossRef
Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
Thyroid.2019; 29(8): 1089. CrossRef
Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients
Lili Ji, Qin Wu, Jun Gu, Xuedong Deng, Wei Zhou, Xing Fan, Feng Zhou
Cancer Imaging.2019;[Epub] CrossRef
Evolving management considerations in active surveillance for micropapillary thyroid carcinoma
Allen S. Ho, Irene Chen, Michelle Melany, Wendy L. Sacks
Current Opinion in Endocrinology, Diabetes & Obesity.2018; 25(5): 353. CrossRef

Thyroid
Star-Shaped Intense Uptake of ¹³¹I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq: Sung Hye Kong, Jung Ah Lim, Young Shin Song, Shinje Moon, Ye An Kim, Min Joo Kim, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park; Endocrinol Metab. 2018;33(2):228-235. Published online May 4, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.228

5,298 View
50 Download
3 Web of Science
3 Crossref

Abstract PDF PubReader ePub

Background

After initial radioactive iodine (RAI) treatment in differentiated thyroid cancer patients, we sometimes observe a star-shaped region of intense uptake of ¹³¹I on whole body scans (WBSs), called a ‘star artifact.’ We evaluated the clinical implications of star artifacts on the success rate of remnant ablation and long-term prognosis.

Methods

Total 636 patients who received ¹³¹I dose of 1.1 GBq for the initial RAI therapy and who did not show distant metastasis at the time of diagnosis were retrospectively evaluated. A negative second WBS was used for evaluating the ablation efficacy of the RAI therapy. Among them, 235 patients (36.9%) showed a star artifact on their first WBS.

Results

In patients with first stimulated thyroglobulin (sTg) levels ≤2 ng/mL, patients with star artifacts had a higher rate of negative second WBS compared with those without star artifacts (77.8% vs. 63.9%, P=0.044), and showed significantly higher recurrence-free survival (P=0.043) during the median 8.0 years (range, 1.0 to 10.0) of follow-up. The 5- and 10-year recurrence rates (5YRR, 10YRR) were also significantly lower in patients with star artifacts compared with those without (0% vs. 4.9%, respectively, P=0.006 for 5YRR; 0% vs. 6.4%, respectively, P=0.005 for 10YRR). However, ablation success rate or recurrence-free survival was not different among patients whose first sTg levels >2 ng/mL regardless of star artifacts.

Conclusion

Therefore, star artifacts at initial RAI therapy imply a good ablation efficacy or a favorable long-term prognosis in patients with sTg levels ≤2 ng/mL.

Citations

Citations to this article as recorded by

Prognostic value of star-shaped intense uptake of 131I in thyroid cancer patients
Liu Xiao, Wen Jie Zhang, Yue Qi Wang, Lin Li
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2021; 40(1): 30. CrossRef
Valores pronósticos de la captación en estrella de 131I en pacientes con cáncer diferenciado de tiroides
L. Xiao, W.J. Zhang, Y.Q. Wang, L. Li
Revista Española de Medicina Nuclear e Imagen Molecular.2021; 40(1): 30. CrossRef
Comparison between planar and single-photon computed tomography images for radiation intensity quantification in iodine-131 scintigraphy
Yusuke Iizuka, Tomohiro Katagiri, Minoru Inoue, Kiyonao Nakamura, Takashi Mizowaki
Scientific Reports.2021;[Epub] CrossRef

Review Article

Thyroid
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians: Young Shin Song, Jung Ah Lim, Young Joo Park; Endocrinol Metab. 2015;30(3):252-262. Published online September 22, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.3.252

5,155 View
64 Download
60 Web of Science
52 Crossref

Abstract PDF PubReader

Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.

Citations

Citations to this article as recorded by

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
Hon-Fan Lai, Jen-Fan Hang, Po-Chung Kuo, Chin-Sung Kuo, San-Fan Yao, Jui-Yu Chen, Chen-Hsen Lee
Annals of Surgical Oncology.2024; 31(5): 3495. CrossRef
Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules
Murui Zhang, Xiaotong Hu, Lunming Liu, Yihong Wang, Junchang Jiang, Hui Li, Weiqiang Fei, Tingting Zhong, Zhinong Jiang
Medicine.2024; 103(4): e35960. CrossRef
The Association of Socioeconomic Factors and Well-Differentiated Thyroid Cancer
Andrew Bonner, Brendon Herring, Rongzhi Wang, Andrea Gillis, Polina Zmijewski, Brenessa Lindeman, Jessica Fazendin, Herbert Chen
Journal of Surgical Research.2023; 283: 973. CrossRef
BRAFV600E and TERT promoter C228T mutations on ThyroSeq v3 analysis of delayed skin metastasis from papillary thyroid cancer: a case report and literature review
Jee-Hye Choi, Hyeong Won Yu, Ja Kyung Lee, Woochul Kim, June Young Choi, Hee Young Na, So Yeon Park, Chang Ho Ahn, Jae Hoon Moon, Sang Il Choi, Ho-Young Lee, Won Woo Lee, Wonjae Cha, Woo-Jin Jeong
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Less is more meets do more with less: Exploring differences in thyroid FNA molecular testing between Asian and Western practices
Michiya Nishino
Cancer Cytopathology.2023; 131(7): 421. CrossRef
Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study
Sultana Razia, Kentaro Nakayama, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Kosuke Kanno, Seiya Sato, Satoru Kyo
Current Oncology.2023; 30(4): 4052. CrossRef
Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia
Dorota Słowińska-Klencka, Bożena Popowicz, Dominika Kulczycka-Wojdala, Bożena Szymańska, Joanna Duda-Szymańska, Martyna Wojtaszek-Nowicka, Krzysztof Kaczka, Mariusz Klencki
Cancers.2023; 15(17): 4287. CrossRef
Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020
Yun Mi Choi, Min-Ju Kim, Jiwoo Lee, Mi Kyung Kwak, Min Ji Jeon, Tae Yong Kim, Eun-Gyoung Hong, Won Bae Kim, Won Gu Kim
Endocrinology and Metabolism.2023; 38(5): 588. CrossRef
遺伝子から頭頸部がんを診る : 甲状腺癌 (分化癌を中心に)
季吉森谷
Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).2023; 126(12): 1277. CrossRef
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
Endocrinology and Metabolism.2023; 38(6): 619. CrossRef
Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma
Xiaojing Wei, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu, Jingxin Mao, Gitana Maria Aceto
BioMed Research International.2022; 2022: 1. CrossRef
Disparities in the impact of the AJCC 8th edition staging system on differentiated thyroid cancer outcomes
Juan A. Santamaria‐Barria, Amanda N. Graff‐Baker, Shu‐Ching Chang, Adam Khader, Anthony J. Scholer, Mary Garland‐Kledzik, Melanie Goldfarb
Head & Neck.2022; 44(10): 2129. CrossRef
Relationship Between The BRAF V600E And Tumor Size, Lymph Node, And Distant Metastasis In Papillary Thyroid Carcinoma
Edmond Rukmana Wikanta, Yan Wisnu Prajoko, Benny Issakh, Hermawan Istiadi, Dik Puspasari
Russian Open Medical Journal.2022;[Epub] CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.)
Chaiho Jeong, Jeonghoon Ha, Moo Il Kang
Endocrinology and Metabolism.2021; 36(1): 205. CrossRef
Molecular pathogenesis of pediatric thyroid carcinoma
Norisato Mitsutake, Vladimir Saenko
Journal of Radiation Research.2021; 62(Supplement): i71. CrossRef
The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification
Chanchal Rana, Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Chan Kwon Jung, Kennichi Kakudo, Andrey Bychkov
Thyroid.2021;[Epub] CrossRef
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation
Tauangtham Anekpuritanang, Maythad Uataya, Apichaya Claimon, Natthawadee Laokulrath, Warut Pongsapich, Paveena Pithuksurachai
OncoTargets and Therapy.2021; Volume 14: 3959. CrossRef
Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis
Xiabin Lan, Hua Bao, Xinyang Ge, Jun Cao, Xiaojun Fan, Qihong Zhang, Kaihua Liu, Xian Zhang, Zhuo Tan, Chuanming Zheng, Ao Wang, Chao Chen, Xin Zhu, Jiafeng Wang, Jiajie Xu, Xuhang Zhu, Xue Wu, Xiaonan Wang, Yang Shao, Minghua Ge
Cancer Science.2020; 111(6): 2163. CrossRef
Did Introducing a New Category of Thyroid Tumors (Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features) Decrease the Risk of Malignancy for the Diagnostic Categories in the Bethesda System for Reporting Thyroid Cytopathology?
Janusz Kopczyński, Agnieszka Suligowska, Kornelia Niemyska, Iwona Pałyga, Agnieszka Walczyk, Danuta Gąsior-Perczak, Artur Kowalik, Kinga Hińcza, Ryszard Mężyk, Stanisław Góźdź, Aldona Kowalska
Endocrine Pathology.2020; 31(2): 143. CrossRef
The Significance of Transcriptomic Signatures in the Multifocal Papillary Thyroid Carcinoma: Two mRNA Expression Patterns with Distinctive Clinical Behavior from The Cancer Genome Atlas (TCGA) Database
Yea Eun Kang, Boyoung Hwang, Ju Hee Lee, Minho Shong, Hyon-Seung Yi, Bon Seok Koo, Dong Jin Lee
International Journal of Thyroidology.2020; 13(1): 1. CrossRef
High Genetic Diversity and No Evidence of Clonal Relation in Synchronous Thyroid Carcinomas Associated with Hashimoto’s Thyroiditis: A Next-Generation Sequencing Analysis
Csaba Molnár, Emese Sarolta Bádon, Attila Mokánszki, Anikó Mónus, Lívia Beke, Ferenc Győry, Endre Nagy, Gábor Méhes
Diagnostics.2020; 10(1): 48. CrossRef
Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population
Marilena Argyropoulou, Aristidis S. Veskoukis, Pagona-Maria Karanatsiou, Aikaterini Manolakelli, Ifigenia Kostoglou-Athanassiou, George Vilaras, Andreas Karameris, Kalliopi Liadaki
Pathology & Oncology Research.2020; 26(1): 347. CrossRef
Predominant DICER1 Pathogenic Variants in Pediatric Follicular Thyroid Carcinomas
Young Ah Lee, Sun-Wha Im, Kyeong Cheon Jung, Eun-Jae Chung, Choong Ho Shin, Jong-Il Kim, Young Joo Park
Thyroid.2020; 30(8): 1120. CrossRef
BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
Suhail Al-Salam, Charu Sharma, Bachar Afandi, Khaled Al Dahmani, Ali S. Al-Zahrani, Amal Al Shamsi, Juma Al Kaabi, Paula Soares
PLOS ONE.2020; 15(4): e0231341. CrossRef
VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
Cancers.2020; 12(3): 596. CrossRef
Highly Sensitive and Specific Molecular Test for Mutations in the Diagnosis of Thyroid Nodules: A Prospective Study of BRAF-Prevalent Population
Yoon Young Cho, So Young Park, Jung Hee Shin, Young Lyun Oh, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Hyun Sook Yim, Yoo-Li Kim, Chang-Seok Ki, Tae Hyuk Kim, Jae Hoon Chung, Sun Wook Kim
International Journal of Molecular Sciences.2020; 21(16): 5629. CrossRef
Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer of thyroid: A genomic linkage study
Ramesh Bangaraiahgari, Ramakanth Bhargav Panchangam, Pradeep Puthenveetil, Sabaretnam Mayilvaganan, Rajesh Bangaraiahgari, Rajkiran reddy Banala, Poongkodi Karunakaran, Rafi Md
Annals of Medicine and Surgery.2020; 60: 695. CrossRef
Genomic Characterization of Differentiated Thyroid Carcinoma
Young Shin Song, Young Joo Park
Endocrinology and Metabolism.2019; 34(1): 1. CrossRef
Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)
Sung Min Lee, Cho Rok Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Journal of Endocrine Surgery.2019; 19(3): 76. CrossRef
Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears
Sergei E. Titov, Mikhail K. Ivanov, Pavel S. Demenkov, Gevork A. Katanyan, Eugenia S. Kozorezova, Anastasia V. Malek, Yulia A. Veryaskina, Igor F. Zhimulev
BMC Cancer.2019;[Epub] CrossRef
Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer
Young Shin Song, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Endocrine-Related Cancer.2019; 26(6): 629. CrossRef
Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice: Perspectives for Surgical Pathology and Cytopathology
Andrey Bychkov, Chan Kwon Jung, Zhiyan Liu, Kennichi Kakudo
Endocrine Pathology.2018; 29(3): 276. CrossRef
Understanding Malignancies of the Thyroid Gland: Institutional Experience
Jaimanti Bakshi, Sourabha Kumar Patro, Navjot Kaur, Naresh Kumar Panda, Grace Budhiraja
Indian Journal of Otolaryngology and Head & Neck Surgery.2018; 70(4): 482. CrossRef
Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
World Journal of Surgery.2018; 42(5): 1424. CrossRef
Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries
Andrey Bychkov, Somboon Keelawat, Shipra Agarwal, Deepali Jain, Chan Kwon Jung, SoonWon Hong, Chiung-Ru Lai, Shinya Satoh, Kennichi Kakudo
Pathology.2018; 50(4): 411. CrossRef
Genetic landscape of papillary thyroid carcinoma in the Chinese population
Jialong Liang, Wanshi Cai, Dongdong Feng, Huajing Teng, Fengbiao Mao, Yi Jiang, Shanshan Hu, Xianfeng Li, Yujie Zhang, Baoguo Liu, Zhong Sheng Sun
The Journal of Pathology.2018; 244(2): 215. CrossRef
Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance
Andrey Bychkov, Chan Kwon Jung
Human Pathology.2018; 71: 74. CrossRef
Molecular markers in well-differentiated thyroid cancer
Anil K. D’Cruz, Richa Vaish, Abhishek Vaidya, Iain J. Nixon, Michelle D. Williams, Vincent Vander Poorten, Fernando López, Peter Angelos, Ashok R. Shaha, Avi Khafif, Alena Skalova, Alessandra Rinaldo, Jennifer L. Hunt, Alfio Ferlito
European Archives of Oto-Rhino-Laryngology.2018; 275(6): 1375. CrossRef
Meta-Analysis Confirms the Deleterious Effects of CombinedBRAFV600Eand Telomerase Reverse Transcriptase Promoter Mutations on the Course and Mortality of Papillary Thyroid Carcinoma
Charles H. Emerson
Clinical Thyroidology.2017; 29(5): 176. CrossRef
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
Cancer Research and Treatment.2017; 49(4): 906. CrossRef
Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan
Naoki Oishi, Tetsuo Kondo, Tadao Nakazawa, Kunio Mochizuki, Tomohiro Inoue, Kazunari Kasai, Ippei Tahara, Tomonori Yabuta, Mitsuyoshi Hirokawa, Akira Miyauchi, Ryohei Katoh
Endocrine Pathology.2017; 28(2): 103. CrossRef
Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm
Seo Ki Kim, Inhye Park, Jung-Woo Woo, Jun Ho Lee, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim
Thyroid.2017; 27(2): 207. CrossRef
Low Rate of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice
Andrey Bychkov, Mitsuyoshi Hirokawa, Chan Kwon Jung, Zhiyan Liu, Yun Zhu, Soon Won Hong, Shinya Satoh, Chiung-Ru Lai, Lien Huynh, Kennichi Kakudo
Thyroid.2017; 27(7): 983. CrossRef
Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer
Young Shin Song, Jung Ah Lim, Hye Sook Min, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
European Journal of Endocrinology.2017; 177(6): 465. CrossRef
Effects of CoexistentBRAFV600EandTERTPromoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park
Thyroid.2017; 27(5): 651. CrossRef
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma
Eun Ji Oh, Sohee Lee, Ja Seong Bae, Yourha Kim, Sora Jeon, Chan Kwon Jung
Endocrine Pathology.2017; 28(1): 49. CrossRef
TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin
Journal of Nuclear Medicine.2017; 58(2): 258. CrossRef
Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(4): 586. CrossRef
TERT promoter mutations and long-term survival in patients with thyroid cancer
Tae Hyuk Kim, Young-Eun Kim, Soomin Ahn, Ji-Youn Kim, Chang-Seok Ki, Young Lyun Oh, Kyunga Kim, Jae Won Yun, Woong-Yang Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung
Endocrine-Related Cancer.2016; 23(10): 813. CrossRef
Reply:
Y. Che
American Journal of Neuroradiology.2016; 37(1): E9. CrossRef
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae‐Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park, Jeong‐Sun Seo
Cancer.2016; 122(9): 1370. CrossRef

First
Prev
Page of 1
Next
Last

Search